2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Amylases

Amylases

Amylases are crucial enzymes which hydrolyze internal glycosidic linkages in starch and produce as primary products dextrins and oligosaccharides. Amylases are classified into α-amylase, β-amylase, and glucoamylase based on their three-dimensional structures, reaction mechanisms, and amino acid sequences. Amylases have innumerable applications in clinical, medical, and analytical chemistries as well as in food, detergent, textile, brewing, and distilling industries.

Amylases Related Products (96):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-168961
    α-Amylase/α-Glucosidase-IN-18
    		Inhibitor
    α-Amylase/α-Glucosidase-IN-18 (Compound 9g) is the inhibitor for α-Amylase and α-Glucosidase with IC50 of 49.17 nM and 10.71 nM. α-Amylase/α-Glucosidase-IN-18 can be used in research of type 2 diabetes mellitus.
    α-Amylase/α-Glucosidase-IN-18
  • HY-155961
    Antidiabetic agent 2
    		Inhibitor
    Antidiabetic agent 2 (Compound 56) is a glucose-uptake promoter. Antidiabetic agent 2 inhibits DPP-4, PTP-1B, α-amylase, and α-glucosidase with IC50s of 0.036, 0.042, 0.241, 0.185 μM. Antidiabetic agent 2 decreases blood glucose levels.
    Antidiabetic agent 2
  • HY-B1393R
    Dehydrocholic acid (Standard)
    		Inhibitor
    Dehydrocholic acid (Dehydrocholate) (Standard) is the analytical standard of Dehydrocholic acid (HY-B1393). This product is intended for research and analytical applications. Dehydrocholic acid (Dehydrocholate) is an orally active hydrocholeretic agent. Dehydrocholic acid modulates Autophagy, reduces serum amylase and lipase levels. Dehydrocholic acid has the effects of promoting choleretic function, protecting the liver, reducing pancreatic damage, and regulating cholesterol metabolism. Dehydrocholic acid can be used in the study of acute biliary pancreatitis and obstructive jaundice.
    Dehydrocholic acid (Standard)
  • HY-161764
    α-Glucosidase-IN-67
    		Inhibitor
    α-Glucosidase-IN-67 (compound 5k) is a potent α-Glucosidase inhibitor with IC50 values of 0.31, 4.51 µM for alpha-glucosidase and alpha-amylase, respectively. α-Glucosidase-IN-67 has the potential for the research of type-2 diabetes.
    α-Glucosidase-IN-67
  • HY-179141
    α-Amylase/α-Glucosidase-IN-23
    		Inhibitor
    α-Amylase/α-Glucosidase-IN-23 (Compound 5e) is a α-Amylase/α-Glucosidase inhibitor with IC50 values of 73.68 nM for α-glucosidase and 146.18 nM for α-amylase. α-Amylase/α-Glucosidase-IN-23 can be used in the research of hypoglycemia.
    α-Amylase/α-Glucosidase-IN-23
  • HY-N9916
    8,3′,4′-Trihydroxyflavone-7-O-β-D-glucopyranoside
    		Inhibitor
    8,3′,4′-Trihydroxyflavone-7-O-β-D-glucopyranoside (Compound 3) is natural product that can be isolated from Bidens bipinnata. 8,3′,4′-Trihydroxyflavone-7-O-β-D-glucopyranoside shows 22% inhibition against α-amylase at 0.556 mg/mL.
    8,3′,4′-Trihydroxyflavone-7-O-β-D-glucopyranoside
  • HY-163439
    α-Amylase/α-Glucosidase-IN-12
    		Inhibitor
    α-Amylase/α-Glucosidase-IN-12 (compound 10k) is a dual inhibitor targeting α-glucosidase and α-amylase with IC50 of 34.52 nM and 24.62 nM, respectively. α-Amylase/α-Glucosidase-IN-12 is an inhibitor designed based on triazolo[4,3-b][1,2,4]triazine and has the potential to be used in diabetes research.
    α-Amylase/α-Glucosidase-IN-12
  • HY-172211
    α-Amylase/α-Glucosidase-IN-17
    		Inhibitor
    α-Amylase/α-Glucosidase-IN-17 (Compound 3) is an inhibitor of α-amylase and α-glucosidase, with IC50 values of 14.61 μM and 25.38 μM, respectively. α-Amylase/α-Glucosidase-IN-17 has certain inhibitory activity against A549 cancer cells. α-Amylase/α-Glucosidase-IN-17 has anti-tumor and anti-diabetic effects.
    α-Amylase/α-Glucosidase-IN-17
  • HY-157537
    α-Amylase-IN-5
    		Inhibitor
    α-Amylase-IN-5 (compound 3a) is a α-amylase inhibitor, with an IC50 of 18.8 mM.
    α-Amylase-IN-5
  • HY-174319
    α-Amylase/α-Glucosidase-IN-20
    		Inhibitor
    α-Amylase/α-Glucosidase-IN-20 (Compound 6b) is a dual inhibitor of α-Amylase and α-Glucosidase with IC50s of 414.57 and 924.15 μM for α-Amylase and α-Glucosidase, respectively. α-Amylase/α-Glucosidase-IN-20 shows a potent anti-diabetic activity, promising for diabetes research.
    α-Amylase/α-Glucosidase-IN-20
  • HY-161944
    α-Amylase-IN-8
    		Inhibitor
    α-Amylase-IN-8 (compound 44) ​​is an α-amylase inhibitor (IC50=58.1 μM). α-Amylase-IN-8 can be used in the research of type 2 diabetes.
    α-Amylase-IN-8
  • HY-149313
    α‑Amylase-IN-1
    		Inhibitor 98.33%
    α Amylase-IN-1 (Compound 11) is an α-Amylase inhibitor with an IC50 value of 0.5509 μM. α Amylase-IN-1 has antioxidant activity with an IC50 value of 53.49 μM for scavenging DPPH free radicals. IC50 can be used in the study of diabetes and oxidative stress-related diseases.
    α‑Amylase-IN-1
  • HY-N12263
    3,5,6,7,8,4'-Hexamethoxyflavone
    		Inhibitor 99.98%
    3,5,6,7,8,4'-Hexamethoxyflavone is a inhibitor of α-Amylase with the inhibitory activity of 28.3% at 500 μM.
    3,5,6,7,8,4'-Hexamethoxyflavone
  • HY-149973
    α-Amylase-IN-4
    α-Amylase-IN-4 (Compd 10y) show maximum inhibition of amylase activity with IC50 value 17.83 ± 0.14 μg/mL.
    α-Amylase-IN-4
  • HY-N12999
    Stigmast-5-en-3-ol
    		Inhibitor
    Stigmast-5-en-3-ol induces cancer cell apoptosis and inhibits proliferation by increasing the production of Bax, Caspase-9, p53, and PARP cleavage and reducing Bcl-xl expression. Stigmast-5-en-3-ol exhibits potent inhibitory activity against glucoamylase and α-amylase and possesses high antioxidant activity. Stigmast-5-en-3-ol can be used in the research of diseases such as leukemia, breast cancer, type 2 diabetes, and obesity.
    Stigmast-5-en-3-ol
  • HY-W207699
    MAO-B-IN-46
    		Inhibitor
    MAO-B-IN-46 (Compound 16) is a selective hMAO-B inhibitor (IC50: 26.8 nM), with weak activity against hMAO-A (IC50: 7.2054 μM). MAO-B-IN-46 (Compound 8) also acts as an α-amylase inhibitor (IC50: 19.46 μM). MAO-B-IN-46 exhibits certain neuroprotective effects and shows no significant toxicity to human gingival fibroblasts and SH-SY5Y cells. Additionally, MAO-B-IN-46 can scavenge DPPH and ABTS free radicals, with IC50 values of 17.86 μM and 17.71 μM, respectively. MAO-B-IN-46 can be used in the research of neurodegenerative diseases such as Parkinson's disease, diabetes, and diseases related to oxidative stress resistance.
    MAO-B-IN-46
  • HY-161461
    E234G HYPE-IN-1
    		Inhibitor
    E234G HYPE-IN-1 (Compound I2.10) is an inhibitor of AMPylation directed by the Huntingtin-interacting protein E (HYPE), possessing low micromolar bioactivity, low cytotoxicity, and blood-brain barrier permeability. E234G HYPE-IN-1 can inhibit the AMPylation of B-cell immunoglobulin-binding protein (BiP), the primary substrate of HYPE. E234G HYPE-IN-1 is suitable for development as a HYPE-specific therapeutic agent for clinical conditions such as neurodegenerative diseases and diabetes.
    E234G HYPE-IN-1
  • HY-179698
    α-Glucosidase-IN-105
    		Inhibitor
    α-Glucosidase-IN-105 is a selective and potent α-Glucosidase inhibitor with an IC50 of 31.36 μM. α-Glucosidase-IN-105 also inhibits α-Amylase (IC50 = 104.2 μM). α-Glucosidase-IN-105 exhibits inhibitory effects comparable to the standard drug \rAcarbose (HY-B0089). α-Glucosidase-IN-105 can be used for the research of type 2 diabetes.
    α-Glucosidase-IN-105
  • HY-159491
    DPP-4-IN-11
    		Inhibitor
    DPP-4-IN-11 (compound 10) is an orally active DPP-4 inhibitor (IC50=2.75 μM) with anti-type 2 diabetes activity. DPP-4-IN-11 exerts its glucose-lowering effect by inhibiting the activities of α-glucosidase (IC50=3.02 μM) and α-amylase (IC50=3.3 μM).
    DPP-4-IN-11
  • HY-162634
    α-Amylase/α-Glucosidase-IN-15
    		Inhibitor
    α-Amylase/α-Glucosidase-IN-15 (compound 6C) is an oral bioactive inhibitor of α-Glucosidase and α-amylase, with the IC50s of 21 μM and 61 μM, respectively.
    α-Amylase/α-Glucosidase-IN-15